Tramadol

What is Tramadol?

Tramadol hydrochloride is a centrally acting opioid analgesic used for the management of moderate to moderately severe pain in adults. It has a dual mechanism of action, combining opioid receptor activity with inhibition of monoamine reuptake. Tramadol is a prescription-only controlled medicine in the majority of EU member states and is available in immediate-release and modified-release formulations.

How does Tramadol work?

Tramadol’s analgesic effect results from two complementary mechanisms that work synergistically:

• Opioid receptor agonism: Tramadol and its active metabolite O-desmethyltramadol (M1) bind to mu-opioid receptors in the central nervous system, inhibiting the ascending transmission of pain signals and modulating pain perception. The M1 metabolite has approximately 200 times the affinity for mu-opioid receptors compared to the parent compound.
• Monoamine reuptake inhibition: Tramadol inhibits the reuptake of serotonin and noradrenaline (norepinephrine) in the central nervous system, pathways that are central to the body’s descending pain-modulation system. This component contributes to tramadol’s efficacy in neuropathic pain.
• Combined analgesia: The interaction between these two mechanisms provides a broader analgesic profile than pure opioids, with some evidence of effectiveness in conditions such as diabetic neuropathy and fibromyalgia.

The extent of the opioid component depends partly on CYP2D6 metabolism. Poor metabolisers produce less M1 metabolite and may experience reduced analgesia; ultra-rapid metabolisers may experience heightened opioid effects.

Who is Tramadol for?

Tramadol is indicated for adults (18 years and over) with moderate to moderately severe pain that is not adequately managed by non-opioid analgesics. Clinical indications typically include:

• Musculoskeletal pain: Severe back pain, joint pain, or soft tissue injuries not responding to NSAIDs or weaker analgesics
• Post-operative pain: Pain following surgical procedures requiring more than mild analgesia
• Neuropathic pain: Pain arising from nerve damage or dysfunction, such as diabetic peripheral neuropathy, postherpetic neuralgia, or radiculopathy
• Cancer-related pain: As part of the WHO analgesic ladder for moderate pain
• Chronic pain conditions: Under specialist supervision when other treatments have been insufficient

Tramadol is not appropriate for children, patients with epilepsy or a lowered seizure threshold, patients taking MAO inhibitors, those in acute opioid withdrawal, and patients with acute intoxication by alcohol, hypnotics, or psychotropic medicines. È necessaria una valutazione medica completa prima di emettere qualsiasi prescrizione.

Posologia

Tramadol is available in immediate-release (IR) and modified-release (MR) formulations. The choice between formulations and the dosing schedule should be determined by a doctor based on the patient’s pain pattern and needs.

Formulation	Starting Dose	Titration	Maximum Daily Dose
Immediate-release (capsules/tablets)	50–100 mg every 4–6 hours	Increase as needed under supervision	400 mg/day
Modified-release (tablets)	100–150 mg twice daily	Increase as clinically needed	400 mg/day
Elderly patients (>75 years)	Lower starting doses	Slower titration	300 mg/day (guidance varies)

Modified-release tablets must be swallowed whole — they must never be crushed, chewed, or broken, as this releases the full dose immediately and risks serious opioid toxicity.

Tramadol should be used at the lowest effective dose for the shortest duration consistent with the patient’s treatment goals.

Effetti collaterali

As with all opioid medicines, Tramadol carries important risks that patients and prescribers should weigh carefully against the benefits of treatment.

Effetti collaterali comuni (possono interessare più di 1 persona su 10)

• Nausea (very common, particularly on initiation)
• Dizziness and vertigo
• Headache
• Drowsiness and sedation
• Constipation
• Dry mouth
• Sweating

Effetti collaterali non comuni ma gravi

• Seizures: Tramadol lowers the seizure threshold and can cause convulsions, particularly at higher doses, in patients with epilepsy, or when combined with medications that lower the seizure threshold (antidepressants, antipsychotics, bupropion). This is one of tramadol’s most clinically significant risks.
• Serotonin syndrome: The combination of tramadol’s serotonin reuptake inhibition with SSRIs, SNRIs, MAO inhibitors, triptans, or linezolid can trigger serotonin syndrome — a potentially life-threatening condition characterised by agitation, confusion, rapid heart rate, high temperature, and muscle rigidity.
• Dependence and withdrawal: Physical and psychological dependence can develop with regular use. Abrupt discontinuation should be avoided; tapering under medical supervision is recommended.
• Respiratory depression: At high doses or when combined with other CNS depressants, tramadol can dangerously suppress breathing.
• Hypoglycaemia: Cases of hypoglycaemia have been reported in patients taking tramadol.

This is not a complete list of side effects. Refer to the EMA-approved Summary of Product Characteristics for full prescribing details.

How to get Tramadol online in Europe

Tramadol is a prescription-only controlled medicine in most EU member states. Non può essere legalmente dispensato senza una prescrizione valida da parte di un professionista medico autorizzato.

Prescrivia opera come piattaforma intermediaria tecnologica: non prescriviamo farmaci, non impieghiamo medici né vendiamo medicinali. La nostra piattaforma mette in contatto i pazienti con medici indipendenti registrati nell’UE che possono condurre valutazioni sanitarie online riservate.

Il processo funziona come segue:

1. Completi una valutazione della salute: Risponda a un insieme strutturato di domande sulla salute covering your medical history, current medications (particularly any serotonergic medicines or CNS depressants), pain history, and prior analgesic use.
2. Revisione medica: Un medico indipendente registrato nell’UE esamina la Sua valutazione. If Tramadol is clinically appropriate for your situation, they may issue a prescription. If it is not appropriate — or if a safer alternative exists — the doctor will advise accordingly.
3. Prescrizione e dispensazione: Se viene emessa una prescrizione, viene inoltrata a una farmacia partner autorizzata dell’UE, che dispensa e spedisce il farmaco direttamente a Lei.

Importante: Prescrivia non garantisce che venga emessa una prescrizione. Tutte le decisioni prescrittive vengono prese in modo indipendente da professionisti medici qualificati in base alle Sue circostanze cliniche individuali.

Informazioni importanti sulla sicurezza

Non utilizzi Tramadol se Lei:

• Are under 18 years of age
• Have epilepsy or a history of seizures
• Are taking or have recently taken MAO inhibitors (within 14 days)
• Are in acute opioid withdrawal
• Have acute alcohol intoxication or are under the influence of hypnotics, opioid analgesics, or psychotropic medicines
• Are known to be an ultra-rapid CYP2D6 metaboliser and at risk of serotonin toxicity

Informi il Suo medico prima di starting Tramadol if you have:

• A personal or family history of epilepsy or seizures
• A history of opioid dependence or substance misuse
• Liver or kidney disease
• Head injury or raised intracranial pressure
• Depression, anxiety, or are taking any antidepressant medication
• Adrenal insufficiency or hypothyroidism
• Prostate enlargement or urinary retention

Interazioni farmacologiche: Tramadol has clinically significant interactions with SSRIs, SNRIs, MAO inhibitors, triptans, linezolid (risk of serotonin syndrome), anticoagulants (warfarin — risk of altered INR), CYP2D6 and CYP3A4 inhibitors and inducers, antiepileptics (carbamazepine reduces tramadol efficacy), and other CNS depressants including alcohol and benzodiazepines. Informi sempre il Suo medico di tutti i farmaci attualmente assunti durante la valutazione.

Modified-release tablets must never be crushed, broken, or chewed.

Fonti

Le informazioni mediche presenti in questa pagina si basano sulle seguenti fonti:

• European Medicines Agency (EMA). Tramadol hydrochloride — Summary of Product Characteristics. Disponibile su: ema.europa.eu
• World Health Organization (WHO). WHO Model List of Essential Medicines — Medicines for pain and palliative care. who.int
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
• Shadnia S, et al. Tramadol intoxication: A review of 114 cases. Hum Exp Toxicol. 2008.

Questo contenuto viene rivisto periodicamente per riflettere le linee guida cliniche aggiornate. Viene fornito esclusivamente a scopo informativo e non costituisce consulenza medica. Consulti sempre un professionista sanitario qualificato per consigli pertinenti alle Sue circostanze di salute individuali.